nodes	percent_of_prediction	percent_of_DWPC	metapath
Varenicline—CHRNA6—head—muscle cancer	0.00457	0.117	CbGeAlD
Varenicline—CHRNB2—smooth muscle tissue—muscle cancer	0.00407	0.104	CbGeAlD
Varenicline—CHRNB2—tendon—muscle cancer	0.00306	0.0783	CbGeAlD
Varenicline—CHRNB2—bone marrow—muscle cancer	0.00296	0.0758	CbGeAlD
Varenicline—CHRNB2—vagina—muscle cancer	0.00284	0.0727	CbGeAlD
Varenicline—CHRNB2—head—muscle cancer	0.00262	0.0671	CbGeAlD
Varenicline—CHRNA3—head—muscle cancer	0.00254	0.0651	CbGeAlD
Varenicline—CHRNB2—testis—muscle cancer	0.00253	0.0648	CbGeAlD
Varenicline—CHRNA7—renal system—muscle cancer	0.00248	0.0635	CbGeAlD
Varenicline—CHRNA3—testis—muscle cancer	0.00246	0.0629	CbGeAlD
Varenicline—Hot flush—Doxorubicin—muscle cancer	0.00209	0.00217	CcSEcCtD
Varenicline—Liver function test abnormal—Methotrexate—muscle cancer	0.00208	0.00217	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00208	0.00217	CcSEcCtD
Varenicline—Increased appetite—Doxorubicin—muscle cancer	0.00208	0.00216	CcSEcCtD
Varenicline—Menopausal symptoms—Doxorubicin—muscle cancer	0.00207	0.00215	CcSEcCtD
Varenicline—Insomnia—Vincristine—muscle cancer	0.00207	0.00215	CcSEcCtD
Varenicline—CHRFAM7A—head—muscle cancer	0.00206	0.0526	CbGeAlD
Varenicline—Malaise—Etoposide—muscle cancer	0.00204	0.00213	CcSEcCtD
Varenicline—Breast disorder—Methotrexate—muscle cancer	0.00204	0.00212	CcSEcCtD
Varenicline—Vertigo—Etoposide—muscle cancer	0.00204	0.00212	CcSEcCtD
Varenicline—Abdominal pain—Dactinomycin—muscle cancer	0.00202	0.0021	CcSEcCtD
Varenicline—Body temperature increased—Dactinomycin—muscle cancer	0.00202	0.0021	CcSEcCtD
Varenicline—Hypoglycaemia—Doxorubicin—muscle cancer	0.002	0.00208	CcSEcCtD
Varenicline—Loss of consciousness—Etoposide—muscle cancer	0.00199	0.00207	CcSEcCtD
Varenicline—Lethargy—Doxorubicin—muscle cancer	0.00199	0.00207	CcSEcCtD
Varenicline—Cerebrovascular accident—Doxorubicin—muscle cancer	0.00199	0.00207	CcSEcCtD
Varenicline—CHRFAM7A—testis—muscle cancer	0.00199	0.0509	CbGeAlD
Varenicline—Decreased appetite—Vincristine—muscle cancer	0.00199	0.00207	CcSEcCtD
Varenicline—Cough—Etoposide—muscle cancer	0.00198	0.00206	CcSEcCtD
Varenicline—Gastrointestinal disorder—Vincristine—muscle cancer	0.00197	0.00205	CcSEcCtD
Varenicline—Fatigue—Vincristine—muscle cancer	0.00197	0.00205	CcSEcCtD
Varenicline—Convulsion—Etoposide—muscle cancer	0.00196	0.00204	CcSEcCtD
Varenicline—Hypertension—Etoposide—muscle cancer	0.00196	0.00204	CcSEcCtD
Varenicline—Pain—Vincristine—muscle cancer	0.00195	0.00203	CcSEcCtD
Varenicline—Constipation—Vincristine—muscle cancer	0.00195	0.00203	CcSEcCtD
Varenicline—Osteoarthritis—Doxorubicin—muscle cancer	0.00195	0.00203	CcSEcCtD
Varenicline—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.00195	0.00203	CcSEcCtD
Varenicline—Asthma—Methotrexate—muscle cancer	0.00195	0.00203	CcSEcCtD
Varenicline—Chest pain—Etoposide—muscle cancer	0.00193	0.00201	CcSEcCtD
Varenicline—Migraine—Doxorubicin—muscle cancer	0.00192	0.002	CcSEcCtD
Varenicline—Affect lability—Doxorubicin—muscle cancer	0.00192	0.002	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00192	0.00199	CcSEcCtD
Varenicline—Discomfort—Etoposide—muscle cancer	0.00191	0.00198	CcSEcCtD
Varenicline—Hypersensitivity—Dactinomycin—muscle cancer	0.00188	0.00196	CcSEcCtD
Varenicline—Abdominal discomfort—Methotrexate—muscle cancer	0.00187	0.00194	CcSEcCtD
Varenicline—Gastrointestinal pain—Vincristine—muscle cancer	0.00187	0.00194	CcSEcCtD
Varenicline—Mood swings—Doxorubicin—muscle cancer	0.00185	0.00192	CcSEcCtD
Varenicline—Infection—Etoposide—muscle cancer	0.00184	0.00191	CcSEcCtD
Varenicline—Asthenia—Dactinomycin—muscle cancer	0.00183	0.00191	CcSEcCtD
Varenicline—Thrombocytopenia—Etoposide—muscle cancer	0.00181	0.00189	CcSEcCtD
Varenicline—Tachycardia—Etoposide—muscle cancer	0.00181	0.00188	CcSEcCtD
Varenicline—Abdominal pain—Vincristine—muscle cancer	0.00181	0.00188	CcSEcCtD
Varenicline—Body temperature increased—Vincristine—muscle cancer	0.00181	0.00188	CcSEcCtD
Varenicline—Liver function test abnormal—Doxorubicin—muscle cancer	0.0018	0.00188	CcSEcCtD
Varenicline—Skin disorder—Etoposide—muscle cancer	0.0018	0.00187	CcSEcCtD
Varenicline—Erectile dysfunction—Methotrexate—muscle cancer	0.00179	0.00187	CcSEcCtD
Varenicline—Dry skin—Doxorubicin—muscle cancer	0.00179	0.00186	CcSEcCtD
Varenicline—Hyperhidrosis—Etoposide—muscle cancer	0.00179	0.00186	CcSEcCtD
Varenicline—Abdominal pain upper—Doxorubicin—muscle cancer	0.00178	0.00186	CcSEcCtD
Varenicline—Photosensitivity reaction—Methotrexate—muscle cancer	0.00178	0.00185	CcSEcCtD
Varenicline—Hypokalaemia—Doxorubicin—muscle cancer	0.00178	0.00185	CcSEcCtD
Varenicline—Breast disorder—Doxorubicin—muscle cancer	0.00176	0.00184	CcSEcCtD
Varenicline—Anorexia—Etoposide—muscle cancer	0.00176	0.00184	CcSEcCtD
Varenicline—Diarrhoea—Dactinomycin—muscle cancer	0.00175	0.00182	CcSEcCtD
Varenicline—Nasopharyngitis—Doxorubicin—muscle cancer	0.00175	0.00182	CcSEcCtD
Varenicline—Infestation NOS—Methotrexate—muscle cancer	0.00174	0.00181	CcSEcCtD
Varenicline—Infestation—Methotrexate—muscle cancer	0.00174	0.00181	CcSEcCtD
Varenicline—Depression—Methotrexate—muscle cancer	0.00173	0.0018	CcSEcCtD
Varenicline—Hypotension—Etoposide—muscle cancer	0.00173	0.0018	CcSEcCtD
Varenicline—Gastritis—Doxorubicin—muscle cancer	0.00173	0.0018	CcSEcCtD
Varenicline—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00172	0.00179	CcSEcCtD
Varenicline—Abdominal distension—Doxorubicin—muscle cancer	0.0017	0.00177	CcSEcCtD
Varenicline—Stomatitis—Methotrexate—muscle cancer	0.00169	0.00176	CcSEcCtD
Varenicline—Conjunctivitis—Methotrexate—muscle cancer	0.00169	0.00176	CcSEcCtD
Varenicline—Dysphagia—Doxorubicin—muscle cancer	0.00169	0.00176	CcSEcCtD
Varenicline—Asthma—Doxorubicin—muscle cancer	0.00169	0.00176	CcSEcCtD
Varenicline—Hypersensitivity—Vincristine—muscle cancer	0.00168	0.00175	CcSEcCtD
Varenicline—CHRNA7—head—muscle cancer	0.00166	0.0425	CbGeAlD
Varenicline—Dyspnoea—Etoposide—muscle cancer	0.00165	0.00172	CcSEcCtD
Varenicline—Somnolence—Etoposide—muscle cancer	0.00164	0.00171	CcSEcCtD
Varenicline—Angina pectoris—Doxorubicin—muscle cancer	0.00164	0.00171	CcSEcCtD
Varenicline—Hepatobiliary disease—Methotrexate—muscle cancer	0.00164	0.00171	CcSEcCtD
Varenicline—Epistaxis—Methotrexate—muscle cancer	0.00164	0.00171	CcSEcCtD
Varenicline—Asthenia—Vincristine—muscle cancer	0.00164	0.00171	CcSEcCtD
Varenicline—CHRNA4—head—muscle cancer	0.00164	0.0419	CbGeAlD
Varenicline—Vomiting—Dactinomycin—muscle cancer	0.00163	0.00169	CcSEcCtD
Varenicline—Bronchitis—Doxorubicin—muscle cancer	0.00162	0.00169	CcSEcCtD
Varenicline—Rash—Dactinomycin—muscle cancer	0.00161	0.00168	CcSEcCtD
Varenicline—Decreased appetite—Etoposide—muscle cancer	0.00161	0.00167	CcSEcCtD
Varenicline—CHRNA7—testis—muscle cancer	0.0016	0.0411	CbGeAlD
Varenicline—Gastrointestinal disorder—Etoposide—muscle cancer	0.0016	0.00166	CcSEcCtD
Varenicline—Fatigue—Etoposide—muscle cancer	0.0016	0.00166	CcSEcCtD
Varenicline—Pain—Etoposide—muscle cancer	0.00158	0.00165	CcSEcCtD
Varenicline—Constipation—Etoposide—muscle cancer	0.00158	0.00165	CcSEcCtD
Varenicline—Diarrhoea—Vincristine—muscle cancer	0.00156	0.00163	CcSEcCtD
Varenicline—Pollakiuria—Doxorubicin—muscle cancer	0.00156	0.00162	CcSEcCtD
Varenicline—Urinary tract disorder—Methotrexate—muscle cancer	0.00154	0.0016	CcSEcCtD
Varenicline—Photosensitivity reaction—Doxorubicin—muscle cancer	0.00154	0.0016	CcSEcCtD
Varenicline—Weight increased—Doxorubicin—muscle cancer	0.00154	0.0016	CcSEcCtD
Varenicline—Urethral disorder—Methotrexate—muscle cancer	0.00153	0.00159	CcSEcCtD
Varenicline—Feeling abnormal—Etoposide—muscle cancer	0.00152	0.00159	CcSEcCtD
Varenicline—Hyperglycaemia—Doxorubicin—muscle cancer	0.00152	0.00158	CcSEcCtD
Varenicline—Nausea—Dactinomycin—muscle cancer	0.00152	0.00158	CcSEcCtD
Varenicline—Gastrointestinal pain—Etoposide—muscle cancer	0.00151	0.00157	CcSEcCtD
Varenicline—Dizziness—Vincristine—muscle cancer	0.00151	0.00157	CcSEcCtD
Varenicline—Infestation NOS—Doxorubicin—muscle cancer	0.0015	0.00157	CcSEcCtD
Varenicline—Infestation—Doxorubicin—muscle cancer	0.0015	0.00157	CcSEcCtD
Varenicline—Visual impairment—Methotrexate—muscle cancer	0.0015	0.00156	CcSEcCtD
Varenicline—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.00149	0.00155	CcSEcCtD
Varenicline—Erythema multiforme—Methotrexate—muscle cancer	0.00147	0.00153	CcSEcCtD
Varenicline—Urticaria—Etoposide—muscle cancer	0.00147	0.00153	CcSEcCtD
Varenicline—Stomatitis—Doxorubicin—muscle cancer	0.00147	0.00153	CcSEcCtD
Varenicline—Body temperature increased—Etoposide—muscle cancer	0.00146	0.00152	CcSEcCtD
Varenicline—Abdominal pain—Etoposide—muscle cancer	0.00146	0.00152	CcSEcCtD
Varenicline—Conjunctivitis—Doxorubicin—muscle cancer	0.00146	0.00152	CcSEcCtD
Varenicline—Eye disorder—Methotrexate—muscle cancer	0.00146	0.00152	CcSEcCtD
Varenicline—Tinnitus—Methotrexate—muscle cancer	0.00145	0.00151	CcSEcCtD
Varenicline—Vomiting—Vincristine—muscle cancer	0.00145	0.00151	CcSEcCtD
Varenicline—Cardiac disorder—Methotrexate—muscle cancer	0.00145	0.00151	CcSEcCtD
Varenicline—Rash—Vincristine—muscle cancer	0.00144	0.0015	CcSEcCtD
Varenicline—Dermatitis—Vincristine—muscle cancer	0.00144	0.0015	CcSEcCtD
Varenicline—Headache—Vincristine—muscle cancer	0.00143	0.00149	CcSEcCtD
Varenicline—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00142	0.00148	CcSEcCtD
Varenicline—Epistaxis—Doxorubicin—muscle cancer	0.00142	0.00148	CcSEcCtD
Varenicline—Angiopathy—Methotrexate—muscle cancer	0.00142	0.00147	CcSEcCtD
Varenicline—Sinusitis—Doxorubicin—muscle cancer	0.00141	0.00147	CcSEcCtD
Varenicline—Immune system disorder—Methotrexate—muscle cancer	0.00141	0.00147	CcSEcCtD
Varenicline—Mediastinal disorder—Methotrexate—muscle cancer	0.00141	0.00146	CcSEcCtD
Varenicline—Chills—Methotrexate—muscle cancer	0.0014	0.00146	CcSEcCtD
Varenicline—Bradycardia—Doxorubicin—muscle cancer	0.00138	0.00143	CcSEcCtD
Varenicline—Mental disorder—Methotrexate—muscle cancer	0.00137	0.00142	CcSEcCtD
Varenicline—Hypersensitivity—Etoposide—muscle cancer	0.00136	0.00142	CcSEcCtD
Varenicline—Erythema—Methotrexate—muscle cancer	0.00136	0.00141	CcSEcCtD
Varenicline—Malnutrition—Methotrexate—muscle cancer	0.00136	0.00141	CcSEcCtD
Varenicline—Nausea—Vincristine—muscle cancer	0.00136	0.00141	CcSEcCtD
Varenicline—Hypoaesthesia—Doxorubicin—muscle cancer	0.00134	0.0014	CcSEcCtD
Varenicline—Urinary tract disorder—Doxorubicin—muscle cancer	0.00133	0.00139	CcSEcCtD
Varenicline—Oedema peripheral—Doxorubicin—muscle cancer	0.00133	0.00138	CcSEcCtD
Varenicline—Dysgeusia—Methotrexate—muscle cancer	0.00133	0.00138	CcSEcCtD
Varenicline—Asthenia—Etoposide—muscle cancer	0.00133	0.00138	CcSEcCtD
Varenicline—Connective tissue disorder—Doxorubicin—muscle cancer	0.00133	0.00138	CcSEcCtD
Varenicline—Urethral disorder—Doxorubicin—muscle cancer	0.00132	0.00138	CcSEcCtD
Varenicline—Back pain—Methotrexate—muscle cancer	0.00131	0.00137	CcSEcCtD
Varenicline—Pruritus—Etoposide—muscle cancer	0.00131	0.00136	CcSEcCtD
Varenicline—Visual impairment—Doxorubicin—muscle cancer	0.0013	0.00135	CcSEcCtD
Varenicline—Vision blurred—Methotrexate—muscle cancer	0.00128	0.00133	CcSEcCtD
Varenicline—Erythema multiforme—Doxorubicin—muscle cancer	0.00128	0.00133	CcSEcCtD
Varenicline—Diarrhoea—Etoposide—muscle cancer	0.00127	0.00132	CcSEcCtD
Varenicline—Eye disorder—Doxorubicin—muscle cancer	0.00126	0.00131	CcSEcCtD
Varenicline—Ill-defined disorder—Methotrexate—muscle cancer	0.00126	0.00131	CcSEcCtD
Varenicline—Tinnitus—Doxorubicin—muscle cancer	0.00126	0.00131	CcSEcCtD
Varenicline—Anaemia—Methotrexate—muscle cancer	0.00126	0.00131	CcSEcCtD
Varenicline—Cardiac disorder—Doxorubicin—muscle cancer	0.00125	0.0013	CcSEcCtD
Varenicline—Angiopathy—Doxorubicin—muscle cancer	0.00123	0.00128	CcSEcCtD
Varenicline—Malaise—Methotrexate—muscle cancer	0.00122	0.00127	CcSEcCtD
Varenicline—Dizziness—Etoposide—muscle cancer	0.00122	0.00127	CcSEcCtD
Varenicline—Immune system disorder—Doxorubicin—muscle cancer	0.00122	0.00127	CcSEcCtD
Varenicline—Vertigo—Methotrexate—muscle cancer	0.00122	0.00127	CcSEcCtD
Varenicline—Mediastinal disorder—Doxorubicin—muscle cancer	0.00122	0.00127	CcSEcCtD
Varenicline—Chills—Doxorubicin—muscle cancer	0.00121	0.00126	CcSEcCtD
Varenicline—Arrhythmia—Doxorubicin—muscle cancer	0.00121	0.00126	CcSEcCtD
Varenicline—Cough—Methotrexate—muscle cancer	0.00118	0.00123	CcSEcCtD
Varenicline—Mental disorder—Doxorubicin—muscle cancer	0.00118	0.00123	CcSEcCtD
Varenicline—Convulsion—Methotrexate—muscle cancer	0.00118	0.00122	CcSEcCtD
Varenicline—Vomiting—Etoposide—muscle cancer	0.00118	0.00122	CcSEcCtD
Varenicline—Malnutrition—Doxorubicin—muscle cancer	0.00118	0.00122	CcSEcCtD
Varenicline—Erythema—Doxorubicin—muscle cancer	0.00118	0.00122	CcSEcCtD
Varenicline—Rash—Etoposide—muscle cancer	0.00117	0.00121	CcSEcCtD
Varenicline—Dermatitis—Etoposide—muscle cancer	0.00117	0.00121	CcSEcCtD
Varenicline—Headache—Etoposide—muscle cancer	0.00116	0.00121	CcSEcCtD
Varenicline—Flatulence—Doxorubicin—muscle cancer	0.00116	0.00121	CcSEcCtD
Varenicline—Chest pain—Methotrexate—muscle cancer	0.00116	0.0012	CcSEcCtD
Varenicline—Arthralgia—Methotrexate—muscle cancer	0.00116	0.0012	CcSEcCtD
Varenicline—Myalgia—Methotrexate—muscle cancer	0.00116	0.0012	CcSEcCtD
Varenicline—Dysgeusia—Doxorubicin—muscle cancer	0.00115	0.0012	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00115	0.00119	CcSEcCtD
Varenicline—Discomfort—Methotrexate—muscle cancer	0.00114	0.00119	CcSEcCtD
Varenicline—Back pain—Doxorubicin—muscle cancer	0.00114	0.00118	CcSEcCtD
Varenicline—Muscle spasms—Doxorubicin—muscle cancer	0.00113	0.00118	CcSEcCtD
Varenicline—Vision blurred—Doxorubicin—muscle cancer	0.00111	0.00115	CcSEcCtD
Varenicline—Infection—Methotrexate—muscle cancer	0.0011	0.00115	CcSEcCtD
Varenicline—Nausea—Etoposide—muscle cancer	0.0011	0.00114	CcSEcCtD
Varenicline—Ill-defined disorder—Doxorubicin—muscle cancer	0.00109	0.00114	CcSEcCtD
Varenicline—Nervous system disorder—Methotrexate—muscle cancer	0.00109	0.00113	CcSEcCtD
Varenicline—Anaemia—Doxorubicin—muscle cancer	0.00109	0.00113	CcSEcCtD
Varenicline—Thrombocytopenia—Methotrexate—muscle cancer	0.00109	0.00113	CcSEcCtD
Varenicline—Agitation—Doxorubicin—muscle cancer	0.00108	0.00112	CcSEcCtD
Varenicline—Skin disorder—Methotrexate—muscle cancer	0.00108	0.00112	CcSEcCtD
Varenicline—Hyperhidrosis—Methotrexate—muscle cancer	0.00107	0.00111	CcSEcCtD
Varenicline—Malaise—Doxorubicin—muscle cancer	0.00106	0.0011	CcSEcCtD
Varenicline—Vertigo—Doxorubicin—muscle cancer	0.00106	0.0011	CcSEcCtD
Varenicline—Anorexia—Methotrexate—muscle cancer	0.00106	0.0011	CcSEcCtD
Varenicline—Syncope—Doxorubicin—muscle cancer	0.00105	0.0011	CcSEcCtD
Varenicline—Palpitations—Doxorubicin—muscle cancer	0.00104	0.00108	CcSEcCtD
Varenicline—Hypotension—Methotrexate—muscle cancer	0.00104	0.00108	CcSEcCtD
Varenicline—Loss of consciousness—Doxorubicin—muscle cancer	0.00103	0.00108	CcSEcCtD
Varenicline—Cough—Doxorubicin—muscle cancer	0.00103	0.00107	CcSEcCtD
Varenicline—Convulsion—Doxorubicin—muscle cancer	0.00102	0.00106	CcSEcCtD
Varenicline—Hypertension—Doxorubicin—muscle cancer	0.00102	0.00106	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00101	0.00105	CcSEcCtD
Varenicline—Insomnia—Methotrexate—muscle cancer	0.001	0.00104	CcSEcCtD
Varenicline—Arthralgia—Doxorubicin—muscle cancer	0.001	0.00104	CcSEcCtD
Varenicline—Chest pain—Doxorubicin—muscle cancer	0.001	0.00104	CcSEcCtD
Varenicline—Myalgia—Doxorubicin—muscle cancer	0.001	0.00104	CcSEcCtD
Varenicline—Anxiety—Doxorubicin—muscle cancer	0.000998	0.00104	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000994	0.00103	CcSEcCtD
Varenicline—Discomfort—Doxorubicin—muscle cancer	0.000989	0.00103	CcSEcCtD
Varenicline—Dyspnoea—Methotrexate—muscle cancer	0.000988	0.00103	CcSEcCtD
Varenicline—Somnolence—Methotrexate—muscle cancer	0.000985	0.00103	CcSEcCtD
Varenicline—Dry mouth—Doxorubicin—muscle cancer	0.000979	0.00102	CcSEcCtD
Varenicline—Dyspepsia—Methotrexate—muscle cancer	0.000975	0.00102	CcSEcCtD
Varenicline—Decreased appetite—Methotrexate—muscle cancer	0.000963	0.001	CcSEcCtD
Varenicline—Oedema—Doxorubicin—muscle cancer	0.00096	0.000999	CcSEcCtD
Varenicline—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000957	0.000996	CcSEcCtD
Varenicline—Fatigue—Methotrexate—muscle cancer	0.000955	0.000994	CcSEcCtD
Varenicline—Infection—Doxorubicin—muscle cancer	0.000953	0.000992	CcSEcCtD
Varenicline—Pain—Methotrexate—muscle cancer	0.000948	0.000986	CcSEcCtD
Varenicline—Shock—Doxorubicin—muscle cancer	0.000944	0.000982	CcSEcCtD
Varenicline—Nervous system disorder—Doxorubicin—muscle cancer	0.000941	0.000979	CcSEcCtD
Varenicline—Thrombocytopenia—Doxorubicin—muscle cancer	0.00094	0.000978	CcSEcCtD
Varenicline—Tachycardia—Doxorubicin—muscle cancer	0.000937	0.000975	CcSEcCtD
Varenicline—Skin disorder—Doxorubicin—muscle cancer	0.000932	0.00097	CcSEcCtD
Varenicline—Hyperhidrosis—Doxorubicin—muscle cancer	0.000928	0.000965	CcSEcCtD
Varenicline—Anorexia—Doxorubicin—muscle cancer	0.000915	0.000952	CcSEcCtD
Varenicline—Feeling abnormal—Methotrexate—muscle cancer	0.000913	0.00095	CcSEcCtD
Varenicline—Gastrointestinal pain—Methotrexate—muscle cancer	0.000906	0.000943	CcSEcCtD
Varenicline—Hypotension—Doxorubicin—muscle cancer	0.000897	0.000933	CcSEcCtD
Varenicline—Urticaria—Methotrexate—muscle cancer	0.00088	0.000916	CcSEcCtD
Varenicline—Body temperature increased—Methotrexate—muscle cancer	0.000876	0.000912	CcSEcCtD
Varenicline—Abdominal pain—Methotrexate—muscle cancer	0.000876	0.000912	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000874	0.00091	CcSEcCtD
Varenicline—Insomnia—Doxorubicin—muscle cancer	0.000868	0.000903	CcSEcCtD
Varenicline—Dyspnoea—Doxorubicin—muscle cancer	0.000856	0.00089	CcSEcCtD
Varenicline—Somnolence—Doxorubicin—muscle cancer	0.000853	0.000888	CcSEcCtD
Varenicline—Dyspepsia—Doxorubicin—muscle cancer	0.000845	0.000879	CcSEcCtD
Varenicline—Decreased appetite—Doxorubicin—muscle cancer	0.000834	0.000868	CcSEcCtD
Varenicline—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000828	0.000862	CcSEcCtD
Varenicline—Fatigue—Doxorubicin—muscle cancer	0.000827	0.000861	CcSEcCtD
Varenicline—Constipation—Doxorubicin—muscle cancer	0.000821	0.000854	CcSEcCtD
Varenicline—Pain—Doxorubicin—muscle cancer	0.000821	0.000854	CcSEcCtD
Varenicline—Hypersensitivity—Methotrexate—muscle cancer	0.000816	0.00085	CcSEcCtD
Varenicline—Asthenia—Methotrexate—muscle cancer	0.000795	0.000827	CcSEcCtD
Varenicline—Feeling abnormal—Doxorubicin—muscle cancer	0.000791	0.000823	CcSEcCtD
Varenicline—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000785	0.000817	CcSEcCtD
Varenicline—Pruritus—Methotrexate—muscle cancer	0.000784	0.000816	CcSEcCtD
Varenicline—Urticaria—Doxorubicin—muscle cancer	0.000762	0.000793	CcSEcCtD
Varenicline—Body temperature increased—Doxorubicin—muscle cancer	0.000759	0.000789	CcSEcCtD
Varenicline—Abdominal pain—Doxorubicin—muscle cancer	0.000759	0.000789	CcSEcCtD
Varenicline—Diarrhoea—Methotrexate—muscle cancer	0.000758	0.000789	CcSEcCtD
Varenicline—Dizziness—Methotrexate—muscle cancer	0.000733	0.000763	CcSEcCtD
Varenicline—Hypersensitivity—Doxorubicin—muscle cancer	0.000707	0.000736	CcSEcCtD
Varenicline—Vomiting—Methotrexate—muscle cancer	0.000705	0.000733	CcSEcCtD
Varenicline—Rash—Methotrexate—muscle cancer	0.000699	0.000727	CcSEcCtD
Varenicline—Dermatitis—Methotrexate—muscle cancer	0.000698	0.000726	CcSEcCtD
Varenicline—Headache—Methotrexate—muscle cancer	0.000694	0.000722	CcSEcCtD
Varenicline—Asthenia—Doxorubicin—muscle cancer	0.000688	0.000716	CcSEcCtD
Varenicline—Pruritus—Doxorubicin—muscle cancer	0.000679	0.000707	CcSEcCtD
Varenicline—Nausea—Methotrexate—muscle cancer	0.000658	0.000685	CcSEcCtD
Varenicline—Diarrhoea—Doxorubicin—muscle cancer	0.000657	0.000683	CcSEcCtD
Varenicline—Dizziness—Doxorubicin—muscle cancer	0.000635	0.00066	CcSEcCtD
Varenicline—Vomiting—Doxorubicin—muscle cancer	0.00061	0.000635	CcSEcCtD
Varenicline—Rash—Doxorubicin—muscle cancer	0.000605	0.00063	CcSEcCtD
Varenicline—Dermatitis—Doxorubicin—muscle cancer	0.000604	0.000629	CcSEcCtD
Varenicline—Headache—Doxorubicin—muscle cancer	0.000601	0.000626	CcSEcCtD
Varenicline—Nausea—Doxorubicin—muscle cancer	0.00057	0.000593	CcSEcCtD
